COEP
Price
$9.39
Change
+$0.25 (+2.74%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
32.12M
YMAB
Price
$4.54
Change
+$0.10 (+2.25%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
201.11M
27 days until earnings call
Interact to see
Advertisement

COEP vs YMAB

Header iconCOEP vs YMAB Comparison
Open Charts COEP vs YMABBanner chart's image
Coeptis Therapeutics Holdings
Price$9.39
Change+$0.25 (+2.74%)
Volume$499
Capitalization32.12M
Y-mAbs Therapeutics
Price$4.54
Change+$0.10 (+2.25%)
Volume$677
Capitalization201.11M
COEP vs YMAB Comparison Chart in %
Loading...
COEP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COEP vs. YMAB commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COEP is a StrongBuy and YMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (COEP: $9.50 vs. YMAB: $4.52)
Brand notoriety: COEP and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COEP: 73% vs. YMAB: 48%
Market capitalization -- COEP: $32.12M vs. YMAB: $201.11M
COEP [@Biotechnology] is valued at $32.12M. YMAB’s [@Biotechnology] market capitalization is $201.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COEP’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 1 green FA rating(s).

  • COEP’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, YMAB is a better buy in the long-term than COEP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COEP’s TA Score shows that 5 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • COEP’s TA Score: 5 bullish, 5 bearish.
  • YMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both COEP and YMAB are a good buy in the short-term.

Price Growth

COEP (@Biotechnology) experienced а +25.99% price change this week, while YMAB (@Biotechnology) price change was +5.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

COEP is expected to report earnings on May 14, 2025.

YMAB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($201M) has a higher market cap than COEP($32.1M). COEP YTD gains are higher at: 66.182 vs. YMAB (-42.273). COEP has higher annual earnings (EBITDA): -9.95M vs. YMAB (-30.39M). YMAB has more cash in the bank: 60.3M vs. COEP (4.27M). YMAB has less debt than COEP: YMAB (603K) vs COEP (2.04M). YMAB has higher revenues than COEP: YMAB (88.7M) vs COEP (62.9K).
COEPYMABCOEP / YMAB
Capitalization32.1M201M16%
EBITDA-9.95M-30.39M33%
Gain YTD66.182-42.273-157%
P/E RatioN/AN/A-
Revenue62.9K88.7M0%
Total Cash4.27M60.3M7%
Total Debt2.04M603K338%
FUNDAMENTALS RATINGS
COEP vs YMAB: Fundamental Ratings
COEP
YMAB
OUTLOOK RATING
1..100
156
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
5565
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for COEP (75) in the null industry. This means that YMAB’s stock grew somewhat faster than COEP’s over the last 12 months.

COEP's Profit vs Risk Rating (95) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as COEP (99) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

COEP's Price Growth Rating (55) in the null industry is in the same range as YMAB (65) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

COEP's P/E Growth Rating (100) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COEPYMAB
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
53%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
46%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
40%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 14 days ago
77%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
COEP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CREV4.620.86
+22.87%
Carbon Revolution Public Limited
AUPH8.390.80
+10.54%
Aurinia Pharmaceuticals
TSEM45.000.46
+1.03%
Tower Semiconductor Ltd
CTAS216.641.35
+0.63%
Cintas Corp
IRBT3.73-0.15
-3.87%
iRobot Corp

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+1.80%
ARWR - YMAB
53%
Loosely correlated
-0.11%
OCUL - YMAB
50%
Loosely correlated
+2.97%
CRSP - YMAB
49%
Loosely correlated
-1.80%
FATE - YMAB
48%
Loosely correlated
+0.87%
IPSC - YMAB
47%
Loosely correlated
-1.20%
More